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4Abstract
Purpose: Disseminated intravascular coagulations (DIC), acute respiratory distress 
syndrome (ARDS), and acute kidney injury (AKI) are major organ dysfunctions that 
occur in patients with sepsis. This study aimed to elucidate the impact of these organ 
dysfunctions on mortality in patients with severe sepsis.
Material and Methods: A prospective observational study was performed in 10 ICUs to 
obtain data from patients with severe sepsis. Multivariate analyses to examine in-
hospital mortality were performed. 
Results: Data of 573 patients were analyzed. In-hospital mortality rate was 19.4% 
(111/573). The incidences of DIC, ARDS, and AKI were 58.4%, 18.7%, and 41.7%, 
while the associated mortality rates were 28.9%, 36.4%, and 31.8%, respectively. In 
multiple regression model, DIC (odds ratio 2.71, 95% confidence interval [CI] 1.45-
5.27) and AKI stage 3 (odds ratio 1.98, 95%CI 1.07-3.63) were significantly associated 
with higher in-hospital all-cause mortality. DIC (hazard ratio 2.58, 95%CI 1.53-4.55) 
and AKI stage 3 (hazard ratio 1.73, 95%CI 1.07-2.80) were also significantly associated 
with longer survival durations. However, severe ARDS was not associated with these 
outcomes.
Conclusions: DIC and AKI are frequent complications in patients with severe sepsis. In 
this study, DIC, and AKI stage 3 were independent risk factors of in-hospital mortality.
Key words
5Sepsis, acute respiratory distress syndrome, acute kidney injury, disseminated 
intravascular coagulation, organ dysfunction
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Introduction
Organ dysfunctions, such as disseminated intravascular coagulations (DIC), acute 
respiratory distress syndrome (ARDS), and acute kidney injury (AKI) are common 
complications in patients with sepsis [1]. Although the incidences of these 
complications varies depending on the clinical criteria, 30-50% of patients with severe 
sepsis have DIC complications with mortality rates from 35-40%, which was twice as 
high as compared with patients without DIC [2-6]. Reports have shown that 32.7% of 
patients with severe sepsis (mortality rate, 41.2%) fulfilled the criteria of ARDS as 
defined by the American–European Consensus Conference (AECC) in 1994 [7, 8]. 
However, the rate of sepsis patients with ARDS complications according to the Berlin 
definition was not reported [9]. A recent report showed that the rates of AKI 
complications in patients with severe sepsis were 72-88% while the mortality rates were 
625-39% [10]. Although the incidences and mortality rates of these organ dysfunctions in 
patients with sepsis were high, the reported incidences varied, and the differences have 
not been fully clarified.
Sequential Organ Failure Assessment (SOFA) score is an assessment system for the 
severity of organ dysfunctions, it creates scores for the respiratory, nervous, and 
cardiovascular systems, as well as the liver, renal and coagulation functions [11]. SOFA 
score has a good predictive ability for in-hospital mortality in patients with suspected 
infections in intensive care units (ICU) [12]. In the updated definition of sepsis (Sepsis-
3), organ dysfunction is defined as an acute increase in SOFA score of 2 points or more 
[13]. Although there are established conceptual and clinical definitions for DIC 
(including Japanese Association of Acute Medicine (JAAM) criteria for DIC [14] and 
International Society on Thrombosis and Hemostasis criteria for DIC [15]), ARDS (the 
Berlin definition for ARDS [9]), and AKI classifications (Acute Kidney Injury Network 
(AKIN) [16] and Kidney Disease: Improving Global Outcomes (KDIGO) [17] ), these 
differ from their respective SOFA scores. Furthermore, the incidence and outcome of 
organ dysfunctions complicating sepsis have not been fully elucidated whereas, septic 
shock, has established definitions and has also been well examined [18].
The aim of the current study was to determine the impact of the individual organ 
dysfunctions (DIC, ARDS and AKI) on mortality in patients with severe sepsis.
7Materials and methods
All data were retrieved from a database named Tohoku Sepsis Registry 
(UMIN000010297 [University hospital Medical Information Network Clinical Trials 
Registry]). Data were collected using a prospective observational study design. The 
study was conducted by 10 institutes, three university hospitals, and seven community 
hospitals, in Tohoku District, northern part of Japan. The Institutional Review Board 
(IRB) of each institution approved the study. All IRBs waived the need for informed 
consent due to the observational study design requiring no treatments beyond the daily 
clinical practice according to the Japanese guideline (Ministry of Education, Culture, 
Sports, Science and Technology, and Ministry of Health, Labour and Welfare, Japan. 
Ethical Guidelines for Medical and Health Research Involving Human Subjects. March 
2015). 
Patient selection and data collection
The Tohoku Sepsis Registry prospectively registered consecutive patients admitted 
to ICUs with severe sepsis and patients having severe sepsis after admission to ICUs or 
general wards from January to December 2015. Severe sepsis and septic shock were 
defined according to the International Sepsis guidelines 2012 [19]. Patients aged < 18 
years were excluded from the current analyses. Information were collected from the 
registry and used in the current analyses. Such information includes age, sex, unit where 
sepsis was diagnosed, pre-existing diseases, medications before admission, septic shock 
8or not. Further, information were also collected on Acute Physiology and Chronic 
Health Evaluation (APACHE) II score [20], SOFA score [11] (upon admission), 
primary infection site, blood culture findings, time from diagnosis to antimicrobial 
administration, and interventions for source control. Others were, vital signs, results of 
laboratory tests on day 1 and 4, and co-existing conditions (DIC, ARDS, and AKI). 
Treatment information included, treatment for shock, treatment with drugs including 
anticoagulants for DIC, immunoglobulins, and sivelestat, renal replacement therapy 
(RRT), RRT for non-renal indications, polymyxin B-immobilized fiber column direct, 
and hemoperfusion; data on durations of ICU and hospital stays, in-ICU and in-hospital 
outcomes were also retrieved.
Definitions and measurements
The severity of DIC was assessed using the JAAM scoring algorithm for DIC [14]. 
Based on the JAAM criteria (JAAM-DIC), patients were considered as having DIC if 
they had scores ≥ 4 on day 1 and/or day 4. ARDS was diagnosed on day 1 and/or day 4 
by the Berlin definitions [9]. AKI was diagnosed using the AKIN criteria from day 1 
through day 3 (AKIN criteria required, at the maximum, creatinine levels in three 
consecutive days, or 24h urine output) [16]. The numbers of ICU- and hospital-free 
days within a 28- and 90-day period were calculated by subtracting the duration of the 
ICU- or hospital-stay from 28 and 90 days, respectively. If a patient died before 
discharge from the ICU or hospital, the ICU- or hospital- free days were calculated as 
9zero. 
The main outcome measurement was all-cause in-hospital mortality. 
Statistical analysis
Categorical and continuous variables were expressed as counts (%), or median 
(interquartile range). Missing values were excluded from each analysis. Values were 
compared using Pearson's chi-square test for the categorical variables, the Mann-
Whitney U test for the continuous variables between two groups and the Kruskal-Wallis 
test among three groups. Independent factors associated with in-hospital mortality rate 
and survival duration were examined using multivariate logistic regression analysis and 
Cox hazard regression model, respectively. In the regression models, the following 
confounders were adjusted for: age, gender, and several factors that showed significant 
differences between survivors and non-survivors at univariate analysis. Data were 
analyzed using JMP® Pro Version 11.0 software (SAS Institute Japan Ltd., Tokyo, 
Japan). All statistical tests were two-sided and P < 0.05 was considered as having a 
significant difference.
Results
Six hundred and sixteen patients were enrolled in the Tohoku Sepsis Registry. 
Forty-three patients withdrew from the aggressive treatment within 4 days of the 
diagnosis of sepsis and were thus excluded. The data for 573 patients were analyzed in 
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the current study (Figure 1). 
Demographics, severity and mortality of the patients 
The median age was 74 (64-83) years and 62% of the patients were male. Median 
APACHE II and SOFA scores were 20 (15-26) and 8 (5-11), respectively. The 
comparison of demographics and severity of sepsis in survivors and non-survivors are 
shown in Table 1. The proportion of non-survivor patients diagnosed as severe sepsis in 
the general wards and ICUs was higher than the emergency department. The 
proportions of survivors and non-survivors with pre-existing diseases were similar. The 
proportion of patients who took steroids and immunosuppressant drugs as daily 
medications before admission was higher in non-survivors than survivors. The scores of 
APACHE II, SOFA, and JAAM-DIC were higher in non-survivors than survivors. The 
non-survivors were more likely to have had septic shock. Overall, patients’ 28-day 
mortality was 12.4% (71/573) while the in-hospital all-cause mortality was 19.4% 
(111/573) (Table 2). The data on infection management, circulation management (for 
resuscitation), anticoagulant therapies, and other additional therapies are shown in 
supplemental Tables 1, 2 and 3, respectively.
Organ dysfunctions
The incidences of DIC, ARDS, and AKI in patients with severe sepsis were 
225/385 (58.4%, 188 cases were missing the values for both fibrin degradation products 
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and D-dimer required for calculating JAAM-DIC score), 107/573 (18.7%), and 239/573 
(41.7%), respectively (Table 1). The non-survivors were more likely to have had organ 
dysfunctions (DIC, ARDS and AKI), compared with the survivors. In-hospital mortality 
rates of patients complicated with DIC, ARDS, and AKI were 28.9%, 36.4%, and 
31.8%, respectively (Table 2). The patients with these organ dysfunctions had two- to 
three-fold higher mortality rates than those without complications (P < 0.05 for DIC, 
ARDS, and AKI). Patients with more severe stages of complications or organ 
dysfunctions had higher mortality rates, 51.4% in patients with severe ARDS and 
37.9% in patients with AKI stage 3 (there were no statistically significant differences 
between severity levels with either ARDS or AKI).
Impact of organ dysfunctions on in-hospital mortality
In addition to age and gender, nine factors and covariates which showed significant 
differences between the survivors and non-survivors in univariate analysis were 
included in the multiple and Cox hazard regression models for in-hospital mortality. 
Among the organ dysfunctions (including their severity levels), in the multiple 
regression model, JAAM-DIC (odds ratio [OR] 2.71, 95% confidence interval [CI] 1.45 
– 5.27) and AKI stage 3 (OR 1.98, 95% CI 1.07 – 3.63) were significantly associated 
with higher in-hospital all-cause mortality, while severe ARDS was not (Table 3). In 
Cox hazard regression model, JAAM-DIC (hazard ratio [HR] 2.58, 95% CI 1.53 – 4.55) 
and AKI stage 3 (HR 1.73, 95% CI 1.07 – 2.80) were also significantly associated with 
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shorter survival duration, while severe ARDS was not (Table 4). When all ARDS 
patients (mild, moderate, and severe ARDS) was included as an explanatory variable 
instead of severe ARDS patients, the odds ratio of ARDS with in-hospital mortality was 
not statistically significant, neither in the logistic regression model (OR 1.13, 95%CI 
0.58-2.15) nor the Cox hazard regression model (HR 0.94, 95%CI 0.57-1.53). Figure 2 
shows the survival curves comparing the patients with and without DIC, severe ARDS, 
and AKI stage 3 (P<0.001, <0.001, and <0.001 respectively, by log-rank test).
Discussion
In the present study, we determined the incidences of DIC, AKI, ARDS and 
associated mortality rates in patients with severe sepsis. The incidences of DIC and AKI 
were high while that of ARDS was low (58.4%, 41.7%, and 18.7%, respectively); the 
associated mortality rates were high (28.9 %, 31.8% and 36.4%, respectively) In 
addition, DIC and AKI stage 3 were significantly associated with worse in-hospital 
mortality and survival duration. To the best of our knowledge, this is the first report 
comparing the incidences and effects on mortality rate of organ dysfunctions in patients 
with sepsis in the same cohort. 
In the current study, the incidence of DIC was 58.4%. This was slightly higher than 
that reported previously (30-50%) [2-6]. The mortality rate in patients with DIC was 
28.9%, and was more than twice as high as those without DIC (11.9%) in the present 
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study. However, the mortality rate in patients with DIC in the present study was lower 
than that reported previously (35-40%) [2-6]. In the current cohort, 186/573 (32.5%) of 
patients took anticoagulant therapy including thrombomodulin, antithrombin, protease 
inhibitors, or the combination of these anticoagulants. 
Incidences (42-78%) and mortality rates (30-70%) in septic patients with AKI 
varied in previous reports [20-24]. One reason for this might be the severity of sepsis in 
subjects in each study. Some studies focused on patients with sepsis based on the 
definition by the International Sepsis Definitions Conference in 2001 [25] which 
included sepsis without organ dysfunction, while other studies focused only on patients 
with septic shock. Another reason might be the definitions and classifications of AKI. 
In previous reports [20-24], the Risk, Injury, Failure, Loss of kidney function, End-
stage kidney disease (RIFLE) criteria [26] or original criteria other than RIFLE, AKIN, 
and KDIGO were used. Recently, the incidence and mortality rates in patients with 
severe sepsis complicating AKI classified by RIFLE, KDIGO, and AKIN were 
compared [10]. The incidences showed slight differences (73-88%) between the 
classifications, while the mortality rates were similar among the classifications (35-
38%). According to Pereira et al., the incidence in patients classified using AKIN was 
72.8% while the mortality rate was 38.3% [10]. Our study focused on patients with 
severe sepsis, and AKI was classified using AKIN. Our findings were based on the 
same classification as in the study by Pereira et al [10]. However, in our study, the 
incidence (41.7%) was much lower, while our mortality rate (31.8%) was similar 
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compared to those reported by Pereira et al [10]. Therefore, further cohort study is 
needed to determine the exact incidence of AKI complicating severe sepsis using the 
same definition and classification of sepsis and AKI. 
Fujishima et al. [8] reported the incidence and mortality rate of the acute lung 
injury (ALI) and ARDS defined by the AECC in 1994 [7]. In this report, incidences of 
ALI and ARDS were 40.2% and 32.7% while the mortality rates were 38.6% and 
41.2%, respectively. In the current study, ARDS was defined using an updated 
definition (the Berlin definition) [9], and the incidence of ARDS (including mild to 
severe ARDS) was 18.7% while the mortality rate was 36.4%. The incidence of ARDS 
was much lower in the current study than that reported by Fujishima et al. [8], although 
the definition of ARDS was not so much different, while the mortality was similar in 
both studies. 
Currently, organ dysfunction is much emphasized in the updated definition of 
sepsis, and SOFA score is applied in the diagnostic criteria of sepsis [13]. However, the 
effect of each organ dysfunction on mortality has not been fully considered. The present 
study provided the novel aspect of organ dysfunctions on the outcomes in patients with 
sepsis. JAAM-DIC and AKI stage 3 were independent risk factors of higher in-hospital 
mortality and were also associated with shorter survival durations, while severe ARDS 
was not, in the current study. The statistical power may not have been strong enough to 
reach the significance level because of the small sample size of only 37 patients 
complicated with severe ARDS in the current cohort. Further cohort study is needed to 
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clarify the impact of ARDS, especially severe ARDS, on patients with sepsis.
Based on the findings in our study, DIC and AKI stage 3 are possible risk factors 
for in-hospital mortality in patients with sepsis. However, preventions and early specific 
treatments targeting these organ dysfunctions other than the general management of 
patients with sepsis have not been established. Anticoagulation therapies may have 
survival benefit for patients with sepsis-induced DIC according to a meta-analysis, 
however, this has not yet been established [27, 28]. For the prevention of AKI, 
hydroxyethyl starch should be avoided in fluid therapy [29]. There is no high level 
evidence for pharmacological and blood purified therapies for AKI [30].  It is therefore 
necessary to develop effective preventions and specific treatments for these organ 
dysfunctions.
Limitations
There are some limitations of the current study. First, the definition of sepsis was 
not according to the new definition presented in 2016 [13], since the current study was 
conducted earlier (2015). The results may differ if the new definition of sepsis is applied 
for the inclusion criteria. Second, the number of patients in the current cohort was not 
large enough to conclude about the incidences of complications (organ dysfunctions) of 
sepsis, especially, the incidence of ARDS. Due to the small number of patients, fewer 
explanatory variables were applied in the multivariate analysis. Third, using KDIGO for 
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the definition of AKI complicated with sepsis has not been confirmed in any guidelines 
or consensus meeting. Although Bellomo et al. recommended the use of KDIGO for the 
definition of AKI in patients with sepsis [30], not KDIGO, but AKIN was used in the 
current study because the current study was commenced before the KDIGO criteria 
announcement [31]. Moreover, the creatinine levels in 7 consecutive days are necessary 
to diagnose AKI by KDIGO criteria; however, creatinine levels on days 5 to 7 were not 
collected in the current study. Therefore, we could not apply the KDIGO criteria to our 
subjects. Pereira et al. showed that the incidence of AKI in patients with sepsis 
according to KDIGO was higher than that according to AKIN (87.5% vs. 72.8%), while 
in-hospital mortality for AKI was not different between KDIGO and AKIN in sepsis 
patients (35.8% vs. 38.3% in any category and 48.3% vs. 56.6% in stage 3) [10]. 
Therefore, further cohort study, collecting data from a greater number of patients and 
using KDIGO criteria to diagnose AKI, is needed to conclude on the impact of organ 
dysfunctions on sepsis.
Conclusions
In this study, the incidence of DIC and AKI was high and that of ARDS was low in 
patients with severe sepsis. In addition, DIC and AKI stage 3 were observed to be the 
independent risk factors of in-hospital mortality in patients with sepsis. Based on these 
findings, it is therefore necessary to establish effective early prevention and specific 
therapeutic strategies for these organ dysfunctions in the management of patients with 
sepsis.
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Figure Legends
Figure 1. Study flow 
Diagnosis at the ED: The patients were transferred to the emergency department (ED) either as 
outpatients or from the other hospitals and were diagnosed as severe sepsis at the ED. Diagnosis 
at the general wards: The patients were diagnosed as severe sepsis following admission to the 
general wards for diagnosis other than severe sepsis. Diagnosis at ICU: The patients were 
diagnosed as severe sepsis after admission to the intensive care unit (ICU) for diagnosis other 
than severe sepsis.
ED, emergency department; ICU, intensive care unit
Figure 2. Survival curves
JAAM, Japanese Association for Acute Medicine; DIC, disseminated intravascular coagulation; 
ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; HR, hazard ratio; CI, 
confidence interval
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Table 1    Patients demographics, severity, and organ dysfunctions in survivors 
and non-survivors
Survivors
N=462
Non-
survivors
N=111
P value
Age, years, median (IQR) 75 (65-83) 73 (64-82) 0.2878 
Male, n (%) 277 (60.0) 78 (70.3) 0.0445
Diagnosed at, n (%) 0.0004
Emergency department 378 (84.0) 72 (16.0)
General wards 61 (70.1) 26 (29.9)
ICU 23 (63.9) 13 (36.1)
Pre-existing disease, n (%)
Cardiovascular disease 75 (16.2) 21 (18.9) 0.5000 
Stroke 64 (13.6) 15 (13.5) 0.9258 
COPD 17 (3.7) 2 (1.8) 0.3211 
Autoimmune disease 22 (4.8) 8 (7.2) 0.2990 
Chronic liver disease 15 (3.3) 3 (2.7) 0.7679 
DM 141 (30.5) 29 (26.1) 0.8280 
Chronic kidney disease 41 (8.9) 16 (14.4) 0.0799 
Malignancy 48 (10.4) 18 (16.2) 0.0842 
Medications before admission, n (%)
24
Steroids 46 (10.0) 23 (20.7) 0.0019 
Immunosuppressant Drugs 14 (3.0) 8 (7.2) 0.0408 
Statin 68 (14.8) 13 (11.7) 0.4052 
Anti-platelets 76 (16.5) 22 (19.8) 0.4082 
β-blocker 48 (10.4) 15 (13.5) 0.3528 
Severity 
Septic shock, n (%) 226 (49.0) 84 (75.7) < 0.0001
APACHE II score (day 1), median (IQR) 18 (14–24) 26 (20–32) < 0.0001
SOFA score (day 1), median (IQR) 7 (5–10) 10 (7–14) < 0.0001
Complicating organs dysfunction
JAAM-DIC score (day 1), median (IQR) 2 (1–4) 4 (2–5) < 0.0001
JAAM-DIC (day 1 and/or day 4), n (%) 160/301 (53.2) 65/84 (77.4) < 0.0001
ARDS (day 1 and/or day 4), n (%) 68 (14.7) 39 (35.1) < 0.0001
Severity of ARDS < 0.0001
  Mild 12 (2.6) 6 (5.4)
  Moderate 38 (8.2) 14 (12.6)
  Severe 18 (3.9) 19 (17.1)
AKI (day 1 through day 3), n (%) 163 (35.3) 76 (68.5) < 0.0001
Stage (AKIN Criteria), n (%) < 0.0001
1 46 (10.0%) 14 (12.6%)
2 40 (8.7%) 15 (13.5%)
25
3 77 (16.7%) 47 (24.0%)
IQR, interquartile range; ICU, intensive care unit; COPD, chronic obstructive 
pulmonary disease; DM, diabetes mellitus; APACHE, acute physiology and chronic 
health evaluation; SOFA, sequential organ failure assessment; JAAM, Japanese 
Association for Acute Medicine; DIC, disseminated intravascular coagulation; ARDS, 
acute respiratory distress syndrome; AKI, acute kidney injury; AKIN, acute kidney 
injury network. 
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Table 2　 
Outcomes in patients with and without DIC, ARDS, and acute kidney injury 
complications
In-hospital 
mortality
ICU-free days Hospital-free 
days
All patients
111/573 
(19.4)
21 (12-25) 56 (0-75)
JAAM-DIC 
(day 1 and/or day 
4)
          
No, n (%)
19/160 (11.9) 21 (13-24) 49 (2-73)
Yes, n (%)
65/225 (28.9) 
*
19 (8-23)* 32 (0-70)*
ARDS (day 1 
and/or day 4)
ARDS (-), n (%) 72/466 (15.5) 22 (16-25) 65 (16-77)
ARDS (+), n (%)
39/107 (36.4) 
*
12 (0-19)* 0 (0-42)*
Mild 6/18 (33.3) 19 (2-23) 17 (0-46)
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Moderate 14/52 (26.9) 12 (6-20) 17 (0-44)
Severe 19/37 (51.4) 12 (0-19) 0 (0-39)
AKI (day 1 
through day 4)
AKI (-), n (%) 35/334 (10.5) 23 (17-25) 68 (33-77)
AKI (+), n (%)
76/239 (31.8) 
*
17 (5-23)* 18 (0-66)*
Stage 1 14/60 (23.3) 20 (7-24) 29 (0-70)
Stage 2 15/55 (27.3) 17 (12-24) 52 (0-73)
Stage 3 47/124 (37.9) 14 (1-22) 0 (0-64)
AKI and its stages were diagnosed according to the Acute Kidney Injury Network 
Criteria.
* P <0.05 when patients with and without complications (organ dysfunctions) were 
compared. Any mortality and free-days were not statistically different among the 
different severity levels in ARDS and AKI.
JAAM, Japanese Association for Acute Medicine; DIC, disseminated intravascular 
coagulation; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; AKI, 
Acute kidney injury. 
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Table 3    Logistic regression model for in-hospital mortality
Odds 
ratio
95% confidential 
interval
JAAM-DIC (day 1 and/or day 4) 2.71 1.45 – 5.27
Acute kidney injury Stage 3 (day 1 
through day 4)
1.98 1.07 – 3.63
Severe ARDS (day 1 and/or day 4) 2.02 0.82 – 4.90
Respiratory tract infections 1.98 1.05 – 3.74
Septic shock 1.34 0.68 – 2.79
Gram-positive cocci positive on blood 
culture 
2.37 1.23 – 4.52
APACHE II day 1 1.05 1.01 – 1.09
Sepsis diagnosed at ICU (vs. ED) 2.78 1.03 – 7.40
Medication steroid 1.64 0.78 – 3.36
Age 1.00 0.98 – 1.02
Gender male 1.17 0.64 – 2.16
JAAM, Japanese Association for Acute Medicine; DIC, disseminated intravascular 
coagulation; ARDS, acute respiratory distress syndrome; APACHE, acute physiology 
and chronic health evaluation; ICU, intensive care unit; ED, emergency department.
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Table 4    Cox hazard regression model for in-hospital mortality
Hazard 
ratio
95% confidential 
interval
JAAM-DIC (day 1 and/or day 4) 2.58 1.53-4.55
Acute kidney injury Stage 3 (day 1 
through day 4)
1.73 1.07-2.80
Severe ARDS (day 1 and/or day 4) 1.40 0.72-2.59
Respiratory tract infections 1.69 1.02-2.77
Septic shock 1.16 0.66-2.16
Gram-positive cocci positive on 
blood culture 
1.78 1.07-2.86
APACHE II day 1 1.04 1.01-1.08
Sepsis diagnosed at ICU (vs. ED) 0.99 0.45-1.99
Medication steroid 1.17 0.65-2.02
Age 1.00 1.01-1.08
Gender male 0.92 0.56-1.54
JAAM, Japanese Association for Acute Medicine; DIC, disseminated intravascular 
coagulation; ARDS, acute respiratory distress syndrome; APACHE, acute physiology 
and chronic health evaluation; ICU, intensive care unit; ED, emergency department.
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Severe sepsis
616 
Withdrawal from the aggressive 
treatment within 4 days 
43
Diagnosis at the ED
450
Diagnosis at ICU 36 Diagnosis at the 
general wards
87 
Figure 1
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